Small-Molecule Targeted Therapies Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

mTOR / PI3K Pathway Inhibitors DMPK and Bioanalytical Services

mTOR / PI3K pathway inhibitor bioanalysis is not a generic targeted-therapy LC-MS/MS workflow. Everolimus and sirolimus require rapalog-aware quantification, CYP3A4 / P-gp interpretation, and robust matrix handling, while temsirolimus adds esterase-linked conversion to sirolimus-related exposure.

Alpelisib brings a PI3K inhibitor context into the same pathway panel. Creative Proteomics develops workflows that separate rapalog assay behavior, prodrug-type activation, CYP3A4 metabolism, Phase I MetID, DDI risk, and custom mTOR / PI3K pathway inhibitor panel design.

Browse mTOR / PI3K Inhibitor Drug Index Request Custom Pathway Inhibitor Method Suppor

Rapalog Assay BehaviorAddress hydrophobic analytes, recovery, carryover, matrix response, and low-level LC-MS/MS performance.

Temsirolimus ActivationConnect parent-drug measurement with esterase conversion and sirolimus-related exposure interpretation.

PI3K / mTOR PanelsSeparate alpelisib-style PI3K workflows from rapalog-type mTOR inhibitor bioanalysis.

mTOR / PI3K Study Logic RAPALOG → ACTIVATION → PI3K PANEL

🧬

Rapalog QuantificationEverolimus and sirolimus need matrix-aware parent-drug LC-MS/MS design.

⚗

Temsirolimus ConversionEsterase-mediated activation links parent analyte to sirolimus-related exposure.

⇄

CYP3A4 / P-gp ContextMetabolism and transporter behavior shape exposure and DDI interpretation.

▦

Pathway Panel OutputCustom panels integrate mTOR inhibitors, activation workflows, and PI3K inhibitor readouts.

Pathway-specific bioanalytical design.We connect rapalog-sensitive assay behavior, CYP3A4 metabolism, P-gp context, esterase activation, MetID, DDI risk, and mTOR / PI3K panel development in one study-aware workflow.

mTOR / PI3K Inhibitor Drug Index

Find the mTOR / PI3K Inhibitor Behind the Study

Route each compound by behavior, not only by pathway name: rapalog parent-drug LC-MS/MS, CYP3A4-mediated MetID, P-gp-associated exposure, esterase-linked activation, PI3K inhibitor bioanalysis, DDI risk, or custom pathway-panel development.

A–Z anchors

Filter by study tagsSelect a field to reveal tags. Multiple tags narrow the index to pathway inhibitors matching all selected values.

4 entries · Page 1 of 2

Analytical Pain Points

What Drives Assay Failure in mTOR / PI3K Pathway Inhibitor Studies?

This page includes rapalog-associated mTOR inhibitors, an esterase-activated temsirolimus workflow, and a PI3K inhibitor with a different pathway position. Assay design must account for hydrophobic analyte behavior, matrix recovery, parent-to-active relationships, CYP3A4 / P-gp exposure drivers, and pathway-panel compatibility.

Rapalog-like compounds need matrix-aware assay design

Everolimus and sirolimus are shaped by hydrophobicity, extraction recovery, carryover, adsorption, and matrix-specific response—not only CYP3A4 / P-gp tags.

Our responseExtraction, chromatographic selectivity, internal standard strategy, matrix-matched calibration, and low-level LC-MS/MS performance optimized for rapalog-associated analytes.

Method Development →

Temsirolimus requires parent-to-active interpretation

Esterase conversion links temsirolimus parent measurement with sirolimus-related exposure. A parent-only assay may miss the activation context.

Our responseActivation-aware workflows that define parent, conversion-related, and active-related analyte needs before method development.

MetID →

PI3K and mTOR inhibitors should not be merged blindly

Alpelisib belongs to a PI3K inhibitor context, while everolimus, sirolimus, and temsirolimus sit closer to mTOR / rapalog logic.

Our responseAnalyte strategy separated by pathway position, enzyme route, transporter relevance, matrix behavior, and expected concentration range.

LC-MS/MS Quantification →

CYP3A4 / P-gp DDI risk needs framing

Exposure shifts may reflect metabolism, transporter behavior, or both. DDI interpretation should not rely on parent-drug concentration alone.

Our responseCYP3A4 metabolism, P-gp context, MetID, and quantitative exposure data integrated into DDI-aware study designs.

DDI Studies →

Pathway panels need compatibility checks

A combined mTOR / PI3K panel may include rapalog-type analytes, activation-linked compounds, and PI3K inhibitors with different assay behavior.

Our responseCustom pathway inhibitor panels with analyte-specific extraction, chromatographic selectivity, internal standard planning, calibration design, and pathway-aware reporting.

Custom Panels →

Focused Service Paths

Four Practical Routes for mTOR / PI3K Pathway Inhibitor Studies

Select the route according to compound behavior: rapalog parent-drug quantification, CYP3A4 metabolism, esterase-linked temsirolimus activation, P-gp / DDI context, or custom mTOR / PI3K pathway panels.

Rapalog and Parent-Drug Quantification

For everolimus, sirolimus, temsirolimus, alpelisib, or related pathway inhibitor concentration data in biological matrices.

Everolimus / sirolimus parent-drug exposure
Rapalog-sensitive LC-MS/MS
Plasma / serum bioanalysis
Tissue or cell lysate quantification

LC-MS/MS Drug Quantification →

CYP3A4 Metabolism and Phase I MetID

For studies where CYP3A4 metabolism or Phase I metabolite formation defines the pathway inhibitor readout.

Everolimus / sirolimus CYP3A4 metabolism
Alpelisib Phase I MetID
Microsome / hepatocyte sample analysis
Parent-to-metabolite interpretation

Metabolite Identification →

Temsirolimus Activation and DDI Context

For esterase conversion, parent-to-active interpretation, P-gp substrate context, or CYP3A4-related DDI risk.

Temsirolimus esterase activation
Parent-to-sirolimus-related interpretation
P-gp context for selected compounds
CYP3A4-linked DDI risk

DDI Studies →

Custom mTOR / PI3K Pathway Panels

For multiple mTOR inhibitors, PI3K inhibitors, pathway-combination panels, matrix comparison, or multi-analyte LC-MS/MS.

Everolimus / sirolimus / temsirolimus panels
Alpelisib-inclusive PI3K / mTOR panels
Rapalog and PI3K inhibitor comparison
Compound-specific extraction and reporting

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted mTOR / PI3K Pathway Inhibitor?

If you are working with a rapalog-type mTOR inhibitor, PI3K inhibitor, esterase-activated pathway inhibitor, CYP3A4 metabolism question, P-gp substrate concern, DDI risk workflow, Phase I MetID requirement, or multi-analyte pathway panel, a parent-only LC-MS/MS method may not be enough.

Share your target pathway inhibitor, matrix, concentration range, CYP3A4 requirement, P-gp / transporter concern, esterase activation requirement, rapalog-like assay concern, MetID objective, DDI risk question, and panel needs.

Target pathway inhibitor and matrix

Expected concentration range

Rapalog-like assay concern

CYP3A4 / P-gp context

Esterase activation requirement

Panel development needs

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →